Preview

Системные гипертензии

Расширенный поиск

Дисфункция эндотелия при артериальной гипертензии: фокус на небиволол.

Об авторе

Николай Александрович Ваулин
ГКБ №29, Москва
Россия


Список литературы

1. Vanhoutte PM. Endothelial dysfunction in hypertension. J Hypertens Suppl. 1996; 14 (5): S83-93.

2. Luscher TF, Tschudi MR, Dohi Y. Resistance arteries in hypertension role of the endothehum. In: Mulvany MJ, Aalkjaer C, Haegerty AM, Nyborg NCB, Strandgaard S (eds). Resistance Arteries, Structure and Function. Elsevier Science Publishers B 1991: 312-5.

3. Rizzoni D, Porteri E, Castellano M et al. Vascular hypertrophy and remodeling in secondary hypertension. Hypertension 1996; 28: 785-90. Cockcroft JR, Chowienczyk PJ, Benjamin N, Ritter JM. Preserved endothelium dependent vascular relaxation in patients with essential hypertension. N Engl J Med 1994; 330: 1036-40.

4. Katusic ZS. Heart and Circulatory Physiology. Am. J Physiol 2001; 281: H981-6.

5. Ignarro LJ, Bug GM, Wood KS. Endothelium derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci 1987; 84: 9265-9. Ignarro LJ. Biosynthesis and metabolism of endotheliumderived nitric oxide. Ann Rev Pharmacol Toxicol 1990; 30: 535-60.

6. Moncada S. The l-arginine nitric oxide pathway. Acta Physiol Scand 1992; 145: 201-22.

7. Rossi M, Taddei S, Fabbri A et al. Cutaneous vasodilation to acetylcholine in patients with essential hypertension. J Cardiovasc Pharmacol 1997; 29: 406-11.

8. Taddei S, Virdis A, Mattei P, Salvetti A. Vasodilation to acetylcholine in primary and secondary forms of human hypertension. Hypertension 1993; 21: 929-33.

9. Lijnder L, Kiowski W, Buhler FR, Luscher TF. Indirect evidence for the release of endothelium-derived relaxing factor in the human forearm circulation in vivo: blunted response in essential hypertension. Circulation 1990; 81: 1762-7.

10. Panza JA, Quyyumi AA, Brush Jr JE, Epstein SE. Abnormal endothelium dependent vascular relaxation in patients with essential hypertension. N Engl J Med 1990; 323: 22-7.

11. Brush JE, Faxon DP, Salmon S et al. Abnormal endothelium-dependent coronary vasomotion in hypertensive patients. J Am Coll Cardiol 1992; 19: 809-15.

12. Taddei S, Virdis A, Ghiadoni L, Salvetti A. Endothelial dysfunction in hypertension: fact or fancy? J Cardiovasc Pharmacol 1998; 32 (Suppl 3): S41-7.

13. Rizzoni D, Castellano M, Porten E et al. Vascular structural and functional alterations before and after the development of hypertension m SHR. Am J Hypertens 1994; 7: 193-200.

14. Rizzoni D, Castellano M, Porten E et al. Delayed development of hypertension after short-term nitren-dipine treatment Hypertension 1994; 24: 131-9.

15. Rizzoni D, Castellano M, Porten E et al. Effects of low and high doses of fosinopnl on the structure and function of resistance arteries Hypertension 1995; 26: 118-23.

16. Rizzoni D, Porteri E, Castellano M et al. Endothelial Dysfunction in Hypertension Is Independent From the Etiology and From Vascular Structure. Hypertension 1998; 31; 335-41.

17. Schiffrin EL, Deng LY. Comparison of effects of angiotensm I-converting enzyme inhibition and beta-blockade for 2 years on function of small arteries from hypertensive patients. Hypertension 1995; 25 (Part 2): 699-703.

18. Schiffrin EL, Deng I-Y. Structure and function of resistance arteries of hypertensive patients treated with a beta-blocker or a calcium channel antagonists J Hyperrens 1996; 14: 1247-55.

19. Umans JG. Less nitric oxide, more pressure, or the converse ? Commentary Lancet 1997; 349: 837-16.

20. Taddei S, Virdis A, Mattei P et al. Defective L-arginine-nitric oxide pathway in offspring of essential hypertensive patients. Circulation 1996; 94: 1298-303.

21. Al Suwaidi JA, Hamasaki S, Higano ST et al. Long term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 2000; 101: 948-54.

22. Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000; 101: 1899-906.

23. Neunteufl T, Heher S, Katzenschlager R et al. Late prognostic value of flow-mediated dilation in the brachial artery of patients with chest pain. Am J Cardiol 2000; 86: 207-10.

24. Heitzer T, Schlinzig T, Krohn K et al. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary disease. Circulation 2001; 104: 2673-8.

25. Perticone F, Ceravolo R, Pujia A et al. Prognostic significance of endothelial dysfunction in hypertensive patients. Circulation 2001; 104: 191-6.

26. Gao YS, Nagao T, Bond RA et al. Nebivolol induces endothelium-dependent relaxations of canine coronary arteries. J Cardiovasc Pharmacol 1991; 17: 964-9.

27. Cockcroft JR, Chowienczyk PJ, Brett SE et al. Nebivolol vasodilates human forearm vasculature: Evidence for an l-arginine/NO dependent mechanism. J Pharmacol Exp Therap 1995; 374: 1067-71.

28. Zanchetti A. Clinical pharmacodynamics of nebivolol: new evidence of nitric oxide-mediated vasodilating activity and peculiar haemodynamic properties in hypertensive patients. Blood Pressure 2004; 13 (Suppl 1): 18-33.

29. Dawes M, Brett SE, Chowienczyk PJ et al. The vasodilator action of nebivolol in forearm vasculature of subjects with essential hypertension. Br J Clin Pharmacol 1999; 48: 460-3.

30. Himmelmann A, Hedner T, Snoeck E et al. Haemodynamic effects and pharmacokinetics of oral dand l-nebivolol in hypertensive patients. Eur J Clin Pharmacol 1996; 51: 259-64.

31. Brett SE, Forte P, Chowienczyk et al. Comparison of the effects of nebivolol and bisoprolol on systemic vascular resistance in patients with essential hypertension. Clin Drug Invest 2002; 22: 355-9.

32. Tzemos N, Lim PO, MacDonald TM. Nebivolol reverses endothelial dysfunction in essential hypertension. A randomized, double blind, cross-over study. Circulation 2001; 104: 511-4.

33. Pasini FA, Garbin U, Nava MC et al. Nebivolol decreases oxidative stress in essential hypertensive patients and increases nitric oxide by reducing its oxidative inactivation J Hypertens. 2005; 23 (3): 589-96.

34. Pasinil AF, Garbin U, Stranieri C et al. doi 10.1038/ajh.2008.260. Nebivolol Treatment Reduces Serum Levels of Asymmetric Dimethylarginine and Improves Endothelial Dysfunction in Essential Hypertensive Patients. Am J Hypertens 2008. Publ online 4 Sept. 2008.

35. Garbina U, Pasinia AF, Stranieria C et al. Nebivolol reduces asymmetric dimethylarginine in endothelial cells by increasing dimethylarginine dimethylaminohydrolase 2 (DDAH2) expression and activity. Pharmacol Res 2007; 56: 515-521.

36. Flather M, Shibata M, Coats A et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005; 26: 215-25.

37. Nodari S, Metra M, Dei Cas L. Beta blocker treatment of the patients with diastolic heart failure and arterial hypertension. A prospective, randomised comparison of the long-term effects of atenolol versus nebivolol. Eur J Heart Fail 2003; 5: 621-7.

38. Kamp O, Sieswerda GT, Visser CA. Favourable effects on systolic and diastolic left ventricular function of nebivolol in comparison to atenolol in patients with uncomplicated essential hypertension. Am J Cardiol 2003; 92: 344-8.

39. Masoli O, Redruello M, Balino NP et al. Use of Nebivolol For the Treatment of Endothelial Dysfunction in Patients With Hypertension: The EDEN Registry. J Cardiovasc Pharmacol 2008; 51 (2): 202-7.

40. Flather M, Shibata M, Coats A et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005; 26: 215-25.


Рецензия

Для цитирования:


Ваулин Н.А. Дисфункция эндотелия при артериальной гипертензии: фокус на небиволол. Системные гипертензии. 2009;(1):11-14.

For citation:


. Endothelium dysfunction at arterial hypertension: focus on nebivolol. Systemic Hypertension. 2009;(1):11-14.

Просмотров: 2


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2075-082X (Print)
ISSN 2542-2189 (Online)